Amid WuXi AppTec‘s withdrawal from the Biotechnology Innovation Organization (BIO) and the still emerging consequences of the proposed US BIOSECURE Act, multiple executives from Chinese biotechs and contract research, development and manufacturing organizations (CDMOs) are embracing a more uncertain future.
The high-profile departure of WuXi, the leading China-based biopharma services company, from the global US-based biotech trade association has sent shockwaves through the sector in China and its further ramifications are just now becoming apparent
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?